Construction of a value assessment framework for antineoplastic agents based on multi-criteria decision analysis in the context of diagnosis related group

This study aims to build a value assessment framework applicable to Chinese health-care institutions for antineoplastic agents in the context of diagnosis related group (DRG). This study constructed the value assessment framework through literature research, Delphi expert consultation method, and analytic hierarchy process. This study used internal consistency reliability to test the reliability of the constructed framework. Exploratory factor analysis and validation factor analysis were used for the validity test. Then, the level stratification of the indicators was set based on the literature data, and the value function of each indicator was constructed using the measuring attractiveness by a categorical based assessment technique method to construct a quantitative value assessment model. This study established a value assessment framework of 7 dimensions and 26 indicators. Reliability and validity analyses of these indicators made 4 indicators excluded. Then, the value functions were constructed for 17 indicators, establishing a quantitative value assessment model. This study constructed an antineoplastic drugs evaluation framework in the context of DRG with good validity and reliability and the corresponding quantitative value assessment model. ● The study constructs an anti-tumor drug evaluation framework to address China’s healthcare reform. ● The framework establishes a drug access standards for hospitals to optimize clinical services. ● It integrate policy impacts into the system to guide policymakers in decision-making.